The HABP4 Knockout A-549 Polyclonal Cells represent a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the HABP4 gene in a human lung adenocarcinoma background. This product provides a heterogeneous pool of cells carrying diverse loss-of-function alleles generated by CRISPR/Cas9-mediated gene editing, enabling robust assessment of HABP4-dependent phenotypes without clonal selection artifacts. The polyclonal format is ideal for pooled functional genomics screens, bulk transcriptomic and proteomic analyses, and experiments where biological noise from genetic heterogeneity is acceptable or desired. Each batch of polyclonal knockout cells is quality-controlled for target gene editing efficiency and validated for wild-type allele depletion, yielding a suitable model system for dissecting HABP4 function in oncogenic stress responses.
Derived from a 58-year-old male with lung adenocarcinoma, the A-549 cell line is a well-characterized model of KRAS-mutant, p53 wild-type non-small-cell lung cancer. These cells exhibit an epithelial morphology and retain key features of alveolar type II pneumocyte differentiation, including surfactant production and tight junction formation, making them relevant for epithelial barrier studies. The A-549 background supports investigation of transcriptional dysregulation in lung adenocarcinoma, as these cells harbor activating KRAS mutations that drive constitutive MAPK and PI3K pathway signaling while maintaining intact p53-mediated stress responses. This genetic context provides a physiologically relevant milieu for examining HABP4??s role in integrating oncogenic signals with transcriptional control and mRNA metabolism.
HABP4 (Ki-1/57) is a phosphoprotein that functions at the interface of transcriptional regulation and pre-mRNA splicing, with documented serine/threonine kinase activity. Mechanistically, HABP4 interacts with chromatin remodeling factor CHD3 and transcriptional corepressor DAXX, linking it to chromatin-mediated gene silencing and epigenetic modulation. It also forms complexes with the splicing factor SFRS1, implicating HABP4 in alternative splicing decisions and mRNA processing. Upstream, HABP4 activity is modulated by PRKACA-mediated phosphorylation in response to cellular stress stimuli, which alters its subnuclear localization and protein interactions. Downstream, HABP4 influences the transcriptional output of target genes, partly through modulation of SFRS1-dependent splicing programs. This molecular network places HABP4 as a critical node coupling stress signaling to post-transcriptional gene regulation.
In the A-549 adenocarcinoma background, disruption of HABP4 is expected to perturb stress-responsive transcription and splicing networks that may contribute to cancer cell survival, proliferation, and adaptation to microenvironmental stress. Given the cell line??s KRAS-driven oncogenic profile and wild-type p53 status, the HABP4 knockout model enables interrogation of synthetic lethal interactions or compensatory mechanisms in a genetically defined lung cancer context. This model is particularly relevant for investigating how transcriptional and splicing dysregulation promotes tumor maintenance, therapy resistance, or metastatic potential in RAS-mutant cancers. The polyclonal nature of the knockout pool further allows detection of heterogeneous responses that mirror intratumoral genetic variation.
Researchers can employ this model in diverse applications, including functional dissection of HABP4-mediated transcriptional regulation via ChIP-seq or luciferase reporter assays, splicing analysis through RNA-seq or RT-PCR-based isoform detection, and characterization of stress response pathways using chemical inducers of oxidative or proteotoxic stress. Standard cell-based assays such as proliferation, apoptosis, and migration panels, combined with drug sensitivity testing against standard-of-care agents (e.g., cisplatin, pemetrexed, or KRAS inhibitors), facilitate target validation and mechanistic studies. The polyclonal format is also compatible with immunoprecipitation and mass spectrometry workflows to map HABP4 interactomes under different conditions. For additional details, batch-specific data, or customized assay support, please contact Ascent Research.
